Literature DB >> 23993190

Clinical aspects of autoimmune rheumatic diseases.

Fiona Goldblatt1, Sean G O'Neill.   

Abstract

Multisystem autoimmune rheumatic diseases are heterogeneous rare disorders associated with substantial morbidity and mortality. Efforts to create international consensus within the past decade have resulted in the publication of new classification or nomenclature criteria for several autoimmune rheumatic diseases, specifically for systemic lupus erythematosus, Sjögren's syndrome, and the systemic vasculitides. Substantial progress has been made in the formulation of new criteria in systemic sclerosis and idiopathic inflammatory myositis. Although the autoimmune rheumatic diseases share many common features and clinical presentations, differentiation between the diseases is crucial because of important distinctions in clinical course, appropriate drugs, and prognoses. We review some of the dilemmas in the diagnosis of these autoimmune rheumatic diseases, and focus on the importance of new classification criteria, clinical assessment, and interpretation of autoimmune serology. In this era of improvement of mortality rates for patients with autoimmune rheumatic diseases, we pay particular attention to the effect of leading complications, specifically cardiovascular manifestations and cancer, and we update epidemiology and prognosis.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23993190     DOI: 10.1016/S0140-6736(13)61499-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  39 in total

Review 1.  Stem cell therapy in autoimmune rheumatic diseases: a comprehensive review.

Authors:  Bin Liu; ShangAn Shu; Thomas P Kenny; Christopher Chang; Patrick S C Leung
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

Review 2.  Can cardiovascular magnetic resonance prompt early cardiovascular/rheumatic treatment in autoimmune rheumatic diseases? Current practice and future perspectives.

Authors:  Sophie I Mavrogeni; Petros P Sfikakis; Theodoros Dimitroulas; Loukia Koutsogeorgopoulou; Gikas Katsifis; George Markousis-Mavrogenis; Genovefa Kolovou; George D Kitas
Journal:  Rheumatol Int       Date:  2018-03-07       Impact factor: 2.631

Review 3.  Interferon regulatory factors: critical mediators of human lupus.

Authors:  Mark A Jensen; Timothy B Niewold
Journal:  Transl Res       Date:  2014-10-13       Impact factor: 7.012

4.  Anti-Ro52 antibody acts on the S5-pore linker of hERG to chronically reduce channel expression.

Authors:  John Szendrey; Shawn M Lamothe; Stephanie Vanner; Jun Guo; Tonghua Yang; Wentao Li; Jordan Davis; Mala Joneja; Adrian Baranchuk; Shetuan Zhang
Journal:  Cardiovasc Res       Date:  2019-08-01       Impact factor: 10.787

Review 5.  Neutrophils in the Pathogenesis of Rheumatic Diseases: Fueling the Fire.

Authors:  Yudong Liu; Mariana J Kaplan
Journal:  Clin Rev Allergy Immunol       Date:  2020-11-05       Impact factor: 8.667

6.  Extrahepatic malignancies in primary biliary cirrhosis: a comparative study at two European centers.

Authors:  Annarosa Floreani; Alice Spinazzè; Llorenc Caballeria; Ana Reig; Nora Cazzagon; Irene Franceschet; Alessandra Buja; Patrizia Furlan; Kenichi Harada; Patrick Sc Leung; M Eric Gershwin; Albert Pares
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

7.  Tear cathepsin S as a candidate biomarker for Sjögren's syndrome.

Authors:  Sarah F Hamm-Alvarez; Srikanth R Janga; Maria C Edman; Sara Madrigal; Mihir Shah; Starleen E Frousiakis; Kavita Renduchintala; Jay Zhu; Seth Bricel; Kimberly Silka; Dianne Bach; Martin Heur; Stratos Christianakis; Daniel G Arkfeld; John Irvine; Wendy J Mack; William Stohl
Journal:  Arthritis Rheumatol       Date:  2014-07       Impact factor: 10.995

Review 8.  Revisiting B cell tolerance and autoantibodies in seropositive and seronegative autoimmune rheumatic disease (AIRD).

Authors:  J N Pouw; E F A Leijten; J M van Laar; M Boes
Journal:  Clin Exp Immunol       Date:  2020-11-15       Impact factor: 4.330

Review 9.  Vascular Endothelial Growth Factor Biology and Its Potential as a Therapeutic Target in Rheumatic Diseases.

Authors:  Thi Hong Van Le; Sang-Mo Kwon
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

10.  Investigation of Newly Diagnosed Drug-Naive Patients with Systemic Autoimmune Diseases Revealed the Cleaved Peptide Tyrosine Tyrosine (PYY 3-36) as a Specific Plasma Biomarker of Rheumatoid Arthritis.

Authors:  Jozsef A Balog; Agnes Kemeny; Laszlo G Puskas; Szilard Burcsar; Attila Balog; Gabor J Szebeni
Journal:  Mediators Inflamm       Date:  2021-06-17       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.